Skip to main content

Amr Wahba

Sep 24, 2026

16:41
Dr. Waba says those are the kinds of factors he weighs in clinical practice.
16:46
Based on the data we have right now, tumor type does make a difference.
16:51
So, for example, some areas in the small bowel, like the ileum, which is sort of the distal or the further part of the small bowels, didn't seem to express as much docking sites for these medications to act upon.
17:07
as compared to people with neuroendocrine tumors or cancers in the pancreas or the duodenum.
17:14
And so the patients with such tumors would be at a higher risk and so would require closer monitoring.
17:23
I think someone with a very low burden of tumors is generally less risk than someone who's got spread tumors throughout their body or a type that is progressively going at a faster rate than we would hope for.
17:41
So these are things that I would think of when making a decision or recommendation as to continuing such medications.

12 MINS LATER

29:32
So for someone living with neuroendocrine cancer, another important part of this conversation is simply making sure everyone involved in your care plan knows you're taking one.
16:41
Dr. Waba says those are the kinds of factors he weighs in clinical practice.
16:46
Based on the data we have right now, tumor type does make a difference.
16:51
So, for example, some areas in the small bowel, like the ileum, which is sort of the distal or the further part of the small bowels, didn't seem to express as much docking sites for these medications to act upon.
17:07
as compared to people with neuroendocrine tumors or cancers in the pancreas or the duodenum.
17:14
And so the patients with such tumors would be at a higher risk and so would require closer monitoring.
17:23
I think someone with a very low burden of tumors is generally less risk than someone who's got spread tumors throughout their body or a type that is progressively going at a faster rate than we would hope for.
17:41
So these are things that I would think of when making a decision or recommendation as to continuing such medications.

12 MINS LATER

29:32
So for someone living with neuroendocrine cancer, another important part of this conversation is simply making sure everyone involved in your care plan knows you're taking one.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.